Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study).

NCT00713518 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT00713518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00713518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study).
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
July 31, 2011
Enrollment
152 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration